Core Viewpoint - The stock of Kexing Pharmaceutical has experienced fluctuations, with a recent decline of 2.06%, while the company shows a year-to-date increase of 11.34% in stock price, indicating mixed market sentiment towards its performance and potential [1]. Financial Performance - For the period from January to September 2025, Kexing Pharmaceutical achieved a revenue of 1.148 billion yuan, representing a year-on-year growth of 10.54% [2]. - The net profit attributable to shareholders for the same period was 111 million yuan, showing a significant year-on-year increase of 547.70% [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for Kexing Pharmaceutical increased by 25.03% to 11,800, while the average circulating shares per person decreased by 19.37% to 17,102 shares [2]. - The stock has seen a net outflow of 8.37 million yuan from major funds, with significant buying and selling activity from large orders [1]. Dividend Distribution - Kexing Pharmaceutical has distributed a total of 51.54 million yuan in dividends since its A-share listing, with 15.78 million yuan distributed over the past three years [3]. Institutional Holdings - As of September 30, 2025, notable institutional shareholders include E Fund Medical Healthcare Industry Mixed A, which is the second-largest shareholder with 2.0621 million shares, a decrease of 1.6069 million shares from the previous period [3]. - Other significant changes in institutional holdings include an increase in shares held by Fortune Tianhui Growth Mixed A/B and a decrease in shares held by Fortune Precision Medical Flexible Allocation Mixed A [3].

Group 1 - The core viewpoint of the news is that Baiotai's stock price has shown fluctuations, with a current price of 25.24 CNY per share and a market capitalization of 10.451 billion CNY [1] - Baiotai's stock has increased by 9.08% since the beginning of the year, with a 2.60% rise in the last five trading days and a 9.93% increase over the last 20 days, while it has decreased by 5.64% over the last 60 days [2] - The company, established on July 28, 2003, focuses on the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [2] Group 2 - As of September 30, 2025, Baiotai reported a revenue of 684 million CNY, representing a year-on-year growth of 17.57%, while the net profit attributable to shareholders was -224 million CNY, showing a year-on-year increase of 38.72% [2] - The company is categorized under the pharmaceutical and biological industry, specifically in the bioproducts sector, and is involved in concepts such as biomedicine and innovative drugs [2] - As of September 30, 2025, the number of shareholders decreased by 0.89% to 9,397, with an average of 44,065 circulating shares per person, which increased by 0.89% [2]

Group 1 - The core indices related to the Sci-Tech Innovation Board, including the Sci-Tech 50 Index, Sci-Tech 100 Index, and Sci-Tech Growth Index, all experienced an increase of approximately 3.6% to 3.7% [1] - The E Fund Sci-Tech 50 ETF (588080) has surpassed a scale of 75 billion yuan, with a tracking error of only 0.26% for 2025 and an excess return of 0.66%, ranking first among comparable products [1] - Small Sci-Tech enterprises in sectors such as electronics, electric power equipment, pharmaceuticals, and computer industries account for over 75% of the total [5] Group 2 - The Sci-Tech Comprehensive Index ETF by E Fund features a low fee rate and tracks the comprehensive index of the Sci-Tech Innovation Board, covering all market securities and focusing on core industries such as artificial intelligence, semiconductors, new energy, and innovative pharmaceuticals [6][7] - The Sci-Tech Growth ETF by E Fund tracks the Sci-Tech Growth Index, which consists of 50 stocks with high growth rates in operating income and net profit, predominantly in the electronics and communications sectors [7]

Core Viewpoint - Junshi Biosciences' stock price has shown fluctuations, with a recent decline of 2.11%, while the company has experienced a year-to-date increase of 12.76% in stock value [1][2]. Group 1: Stock Performance - As of January 14, Junshi Biosciences' stock price is reported at 38.52 CNY per share, with a trading volume of 4.05 billion CNY and a market capitalization of 39.548 billion CNY [1]. - The stock has increased by 12.76% year-to-date, with a 1.90% rise over the last five trading days and a 5.30% increase over the last 20 days, while it has slightly decreased by 0.39% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Junshi Biosciences achieved a revenue of 1.806 billion CNY, representing a year-on-year growth of 42.06%. However, the net profit attributable to shareholders was -596 million CNY, reflecting a year-on-year increase of 35.72% in losses [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Junshi Biosciences is 35,900, which is an increase of 15.17% compared to the previous period. The average number of circulating shares per shareholder is 21,361, a decrease of 12.96% [2]. - Among the top ten circulating shareholders, E Fund's SSE STAR 50 ETF holds 19.3929 million shares, a decrease of 2.8203 million shares from the previous period, while Huaxia's SSE STAR 50 ETF holds 18.9720 million shares, down by 1.0745 million shares [3].

Group 1 - The core viewpoint highlights the competitive advantages of Chinese CXO companies in the chemical pharmaceutical sector, particularly in talent, chemical capabilities, compliance production capacity, and intellectual property protection, which are expected to maintain a strong irreplaceability over the next five years [1] - In the biopharmaceutical sector, the revenue growth rate of CDMO companies in South Korea and Japan is higher compared to domestic counterparts, while global competition includes companies from the US and Europe, with WuXi AppTec's market share in the CRDMO field continuing to rise [1] - Two long-term factors to observe include the potential structural limitations on overseas orders for Chinese companies due to the global biopharmaceutical supply chain restructuring driven by the "biopharmaceutical alliance," and the impact of the implementation of the "Biological Safety Law" on the international business of Chinese CXO companies [1] Group 2 - The Innovation Drug ETF Guotai (517110) tracks the SHS Innovation Drug Index (931409), which selects innovative pharmaceutical companies from the Shanghai, Shenzhen, and Hong Kong markets, covering both biopharmaceuticals and chemical pharmaceuticals [2] - The index focuses on companies with outstanding R&D capabilities and excellent growth potential, reflecting the overall performance of the innovative drug industry with a significant growth-oriented investment style [2]

2026年1月6日，复旦大学经济学院举办了"南土国际金融政策圆桌会第9期"，同时也是"如何看待当前宏 观金融形势系列"的第二场活动。本次圆桌会聚焦"当前贸易顺差问题"，与会学者围绕贸易结构转型、 全球价值链把控以及国内外需失衡等多重因素，系统分析了中国贸易顺差创历史新高的深层原因，并深 入探讨了中国在应对外部保护主义挑战、化解国内内卷式竞争及提升外汇与金融安全稳定性等方面面临 的现实制约及可行战略选择。 东吴证券首席经济学家芦哲指出，2025年前11个月，中国贸易顺差规模创历史新高，首次突破万亿美元 大关。虽然贸易顺差总量创历史新高，但其占GDP比重在全世界仍属中等水平。同时，顺差增长背后也 伴随着市场结构的深刻调整。芦哲认为，与2018年相比，中国贸易顺差的市场结构已发生深刻变化：美 欧市场占比明显下降，而"一带一路"沿线国家和新兴市场的重要性显著提升。这种多元化的市场布局， 为中国应对外部经贸摩擦提供了更稳健的战略回旋空间。 探究其中的原因，芦哲进一步分析认为，顺差结构的改善根植于国内产业与产品体系的深度升级。随着 加工贸易占比显著下降，技术密集型且具备较强定价权的产品已成为出口支柱。这不仅提升了中国在全 ...

Market Overview - The Hong Kong stock index opened slightly higher and experienced fluctuations before rising, with the Hang Seng Index up 0.92% at 27,094.31 points, the Hang Seng Tech Index up 1.54% at 5,960.07 points, and the National Enterprises Index up 0.89% at 9,367.75 points [1] - Major tech stocks saw gains, with Alibaba up 5.25%, Tencent Holdings up 1.67%, and Kuaishou up 5.48%, while Meituan fell by 2.96% [1] - AI-related stocks surged, particularly in the AI healthcare sector, with Alibaba Health rising over 16% and a cumulative increase of 50% for the month [1] - Cryptocurrency-related stocks also performed well, with Blue Ocean Interactive rising over 11% [1] - Chinese brokerage stocks generally rose, with Xingsheng International up over 8% [1] - Some sectors, including aviation, electricity, insurance, and domestic banks, saw declines [1] Company News - Q Technology (01478.HK) announced an expected net profit growth of approximately 400% to 450% for the year ending December 31, 2025 [2] - China Coal Energy (01898.HK) projected a 10.2% decrease in coal sales to approximately 256 million tons for 2025, with December sales down 23% year-on-year [2] - Zhixing Technology (01274.HK) was selected as a supplier for a Korean automotive group's driver assistance solutions for four vehicle models [2] - Country Garden (00832.HK) reported a 16.3% decrease in property contract sales to 8.467 billion yuan for 2025 [3] - Hopson Development Holdings (00754.HK) projected a total contract sales of approximately 15.607 billion yuan for 2025, down 6.15% year-on-year [4] - Chuangjie Tong (01588.HK) issued a profit warning, expecting a profit attributable to shareholders between 76 million and 85 million yuan for 2025, representing a growth of 127% to 154% [4] - Suoteng Juchuang (02498.HK) estimated laser radar product sales of approximately 912,000 units for 2025 [5] - Xiaocaiyuan (00999.HK) plans to establish a joint venture to develop an online mall and "community ready-to-eat stores" [6] - GDS Holdings Limited (09698.HK) recovered approximately 95% of the investment principal from DayOne, with an investment return rate of nearly 6.5 times [7] - China Biologic Products (01177.HK) plans to acquire 100% of Hejiya for a maximum base price of 12 million yuan to accelerate the development of its siRNA liver delivery platform [7] - Junshi Biosciences (02696.HK) received acceptance from the FDA for the Biologics License Application (BLA) for Hanbeitai® (Bevacizumab Injection) [7] - Xiaomi Group (01810.HK) repurchased 4 million shares for 152 million HKD at prices between 37.94 and 38.04 HKD [8] - Tencent Holdings (00700.HK) repurchased 1.012 million shares for 636 million HKD at prices between 623 and 638 HKD [9] - Sunny Optical Technology (02382.HK) repurchased 640,000 shares for approximately 41.788 million HKD at prices between 64.55 and 65.8 HKD [10] Institutional Insights - Dongwu Securities noted limited opportunities for the Federal Reserve to cut interest rates this year, suggesting that the rebound of Hong Kong stocks will depend on fundamental conditions [11] - The firm maintains a "barbell strategy" for overall allocation, recommending a focus on value dividends and sectors like AI technology, non-ferrous metals, and innovative pharmaceuticals [11] - China Merchants Securities highlighted that the recent lagging performance of Hong Kong stocks compared to A-shares is due to overseas liquidity dynamics, with a 95.6% probability of the Fed pausing rate cuts in January [11] - The firm anticipates that the recovery of sentiment will drive southbound capital to boost the Hong Kong tech sector [11] - Industrial Securities recommends prioritizing leading internet companies in the AI sector and suggests focusing on dividend assets in low-interest-rate environments [11] - Zheshang International expressed optimism for sectors benefiting from policy support, including new energy, innovative pharmaceuticals, and AI technology, and expects the Hong Kong market to be driven by "AI applications + PPI improvement + expanded domestic demand" in the spring of 2026 [11]

Core Viewpoint - The article discusses the upcoming 20th Private Equity Fund Development Forum, focusing on the theme of "Walking Towards the Light, Stars and Rivers for Miles," which aims to explore new paths for high-quality development in China's private equity fund industry through discussions on AI empowerment, investment opportunities in equity markets, and the value of CTA strategy allocation [2]. Group 1: Market Outlook and Investment Strategies - From a cyclical perspective, the market is expected to be in an upward phase from early 2024 to 2025, with overall valuations still in a bull market mid-stage, indicating no extreme bubbles yet [4]. - AI is identified as a key investment theme for 2026, with a potential shift in focus from hardware to software as commercialization progresses, correcting the current imbalance in AI hardware investment [5]. - The market confidence has been restored due to supportive policies, declining risk-free rates, and improved profit expectations, leading to a cautious optimism for 2026 [5][6]. Group 2: Sector-Specific Insights - The AI industry is seen as having significant growth potential, comparable to the early stages of the internet and new energy revolutions, with a low penetration rate and vast development space [6]. - The investment focus should be on AI applications and innovative pharmaceuticals, with expectations that China could capture 20%-30% of the global innovative drug market share in the next decade [9]. - The consumer sector is expected to require a clear economic recovery and income growth for substantial gains, while the pharmaceutical sector remains promising due to aging trends [11]. Group 3: Macro-Economic Factors - The current market is characterized by a new Kondratiev wave driven by AI, alongside a transition in the global monetary system, with liquidity easing being a primary driver of market growth since September 2024 [14]. - Investment in large projects is highlighted as a significant variable for 2026, particularly in cyclical industries, while the RMB exchange rate is expected to remain stable until October 2026 [15].

Core Viewpoint - The stock of Hotgen Biotech has shown a mixed performance in recent trading, with a year-to-date increase of 18.12% but a slight decline over the past five days, indicating potential volatility in investor sentiment [1]. Financial Performance - For the period from January to September 2025, Hotgen Biotech reported a revenue of 310 million yuan, representing a year-on-year decrease of 19.80% [2]. - The company experienced a net loss attributable to shareholders of 109 million yuan, which is a significant decline of 168.12% compared to the previous year [2]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.90% to 7,833, while the average number of circulating shares per person decreased by 11.43% to 11,835 shares [2]. - The stock price reached 191.36 yuan per share with a market capitalization of 17.741 billion yuan, and the trading volume was 168 million yuan, indicating active market participation [1]. Dividends and Institutional Holdings - Since its A-share listing, Hotgen Biotech has distributed a total of 440 million yuan in dividends, with 17.344 million yuan paid out in the last three years [3]. - Among the top ten circulating shareholders, notable changes include a decrease in holdings by Huatai-PineBridge Innovation Medicine Mixed Fund and an increase by ICBC Frontier Medical Stock A [3].

Market Overview - The Hong Kong stock market opened slightly higher on January 13, with the Hang Seng Index at 26,971.97 points, up 123.50 points, representing a 0.46% increase [2] - The Hang Seng Tech Index opened at 5,894.63 points, gaining 24.84 points, which is a 0.42% rise [4] Company Focus - Haidilao (HK06862) saw its stock rise over 10% in early trading [6] - On January 13, Haidilao announced changes in its board of directors, including the resignation of CEO and executive director Gou Yiqun, and the appointment of Zhang Yong, the company's co-founder, as the new CEO [7] - Zhang Yong previously served as CEO until March 2022, and the board adjustments are part of a strategic realignment [7] Sector Performance - Technology stocks showed mixed performance, with Alibaba rising over 3%, Kuaishou up over 4%, and Baidu and Tencent increasing by over 1%, while JD.com fell nearly 1% [7] - The innovative drug sector continued its upward trend, with BeiGene rising over 3% [7] - The metals sector was active, with Zijin Mining increasing by over 1% [7] - Lithium battery stocks opened higher, with CATL rising over 1% [7] Market Outlook - Brokerages indicate that liquidity in the Hong Kong market is gradually recovering, with net inflows from southbound funds totaling HKD 41.296 billion since the beginning of 2026 [9] - The market is expected to benefit from three converging factors: rising expectations for overseas liquidity easing, accelerated capital inflows, and upward revisions in profit expectations, suggesting a potential upward trend for the Hong Kong stock market [9]